NEW
#EHRA2024 Late-Breaking Interview 💫Dr @JNikorowitsch outlines a substudy of the NOAH-AFNET 6 trial on the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected AF.
📽️👉
tinyurl.com/zwufsuvf
📊No statistically significant differences between
#edoxaban and placebo with comparable stroke rates.
🛑Those receiving edoxaban had more bleeding events and higher rates of all-cause mortality.
#EPeeps #CardioTwitter